Market Overview:

The newborn screening market is experiencing rapid growth, driven by rising prevalence of congenital disorders, government support and mandated programs, and technological advancements in screening methods. According to IMARC Group's latest research publication, "Newborn Screening Market Report by Product (Instruments, Reagents), Technology (Tandem Mass Spectrometry, Pulse Oximetry, Enzyme Based Assay, DNA Assay, Electrophoresis, and Others), Test Type (Dry Blood Spot Test, CCHD, Hearing Screen), and Region 2025-2033", The global newborn screening market size was valued at USD 1,089.3 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 1,818.1 Million by 2033, exhibiting a CAGR of 5.9% from 2025-2033.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Download a sample PDF of this report: https://www.imarcgroup.com/newborn-screening-market/requestsample

Our report includes: 

• Market Dynamics
• Market Trends And Market Outlook
• Competitive Analysis
• Industry Segmentation
• Strategic Recommendations

Growth Factors Driving the Newborn Screening Industry

• Rising Prevalence of Congenital Disorders:

The growing number of newborns with congenital disorders is a major driver for the newborn screening industry. According to the World Health Organization, around 240,000 newborns die annually within the first 28 days due to congenital issues, with an additional 170,000 children passing away before age five. This alarming statistic highlights the urgent need for early detection to prevent long-term health complications. Governments are stepping up, with programs like the U.S. Newborn Screening Program and Texas Department of State Health Services mandating screenings for conditions like spinal muscular atrophy. Early diagnosis through screening allows timely interventions, improving outcomes and reducing healthcare costs. As more parents and healthcare providers recognize the life-saving potential of these tests, demand for advanced screening technologies continues to surge, fueling industry growth.

• Government Support and Mandated Programs:

Government initiatives are pushing the newborn screening industry forward by making screenings mandatory and providing funding. In the U.S., all states enforce newborn screening programs, with the CDC noting that one in every 33 newborns has a congenital impairment. Globally, countries like India and China are expanding screening through national health policies, driven by high birth rates and rising healthcare budgets. For instance, Kenya’s Ministry of Health has partnered with private labs to deliver dried blood spot tests in urban centers. These programs ensure broader access to screening, especially in underserved areas. Financial support, like WHO and UNICEF grants in Sub-Saharan Africa, also boosts infrastructure for screening facilities. This global push for early detection through policy and funding is significantly expanding the market’s reach and impact.

• Technological Advancements in Screening Methods:

Innovations in screening technologies are transforming the newborn screening industry, making tests faster and more accurate. Tandem mass spectrometry, used in 23.8% of screenings, allows detection of multiple disorders from a single sample, improving efficiency. Companies like Revvity recently launched a next-generation sequencing panel, enhancing genetic disorder detection. Similarly, Masimo introduced a real-time baby monitoring system, streamlining data collection. These advancements reduce false positives and enable broader disorder panels, meeting the growing demand for comprehensive testing. With 70% of the market relying on blood tests, technologies like DNA assays are gaining traction in urban hospitals. As healthcare systems adopt these cutting-edge tools, the industry grows, driven by the promise of better outcomes through early and precise diagnosis.

Trends in the Global Newborn Screening Market

• Integration of AI and Machine Learning:

Artificial intelligence (AI) and machine learning are reshaping newborn screening by improving accuracy and efficiency. These technologies analyze complex data from blood tests, reducing errors in detecting disorders like cystic fibrosis. For example, AI-driven platforms can process tandem mass spectrometry results faster, identifying patterns that might be missed by traditional methods. In 2024, instruments accounted for 65.3% of market revenue, with AI integration enhancing their capabilities. Hospitals in North America are adopting AI tools to streamline workflows, ensuring quicker diagnoses. This trend is particularly impactful in high-volume settings, where rapid results are critical. As AI continues to evolve, it’s making screening more accessible and reliable, especially in regions with limited trained staff, driving global adoption of advanced screening solutions.

• Expansion of Screening Panels:

The trend of expanding screening panels is gaining momentum as healthcare systems aim to detect more disorders early. Panels now include rare conditions like spinal muscular atrophy and severe combined immunodeficiency, with over 20 countries adopting DNA-based assays in urban centers. In 2024, dried blood spot tests held a 46.7% market share due to their ability to screen multiple disorders from one sample. For instance, Trivitron Healthcare’s new Centre of Excellence in India focuses on expanding genomic screening capabilities. This trend is driven by growing awareness among parents and providers, pushing for comprehensive testing. As panels grow, they address region-specific health challenges, like sickle cell anemia in Sub-Saharan Africa, enhancing early intervention and improving newborn health outcomes worldwide.

• Growth of Point-of-Care Diagnostics:

Point-of-care (POC) diagnostics are emerging as a game-changer in newborn screening, offering rapid results in settings like maternity clinics. Technologies like pulse oximetry, used for detecting critical congenital heart disease, are increasingly popular, especially in low-resource areas. In 2024, reagents and consumables accounted for over 60% of procurement budgets in national programs, reflecting demand for portable, ready-to-use kits. For example, Kenya’s mobile health units use solar-powered diagnostic tools to screen in remote areas. These innovations reduce reliance on centralized labs, making screening more accessible. As healthcare providers prioritize speed and convenience, POC diagnostics are expanding, particularly in emerging markets like Southeast Asia, where infrastructure is improving, enabling timely interventions for newborns.

Leading Companies Operating in the Global Newborn Screening Industry:

• Agilent Technologies Inc.
• Baebies Inc.
• Bio-RAD Laboratories Inc.
• Chromsystems Instruments & Chemicals GmbH
• Danaher Corporation
• Masimo Corporation
• Medtronic plc
• Natus Medical Incorporated
• Perkinelmer Inc.
• RECIPE Chemicals + Instruments GmbH
• Thermo Fisher Scientific Inc.
• Trivitron Healthcare
• Waters Corporation

Newborn Screening Market Report Segmentation:

By Product:

• Instruments
• Reagents

Instruments represent the largest segment due to their essential role in performing and automating various screening tests.

By Technology:

• Tandem Mass Spectrometry
• Pulse Oximetry
• Enzyme Based Assay
• DNA Assay
• Electrophoresis
• Others

Tandem mass spectrometry accounts for the majority of the market share because of its high accuracy and ability to screen for multiple conditions simultaneously from a single sample.

By Test Type:

• Dry Blood Spot Test
• CCHD
• Hearing Screen

Dry blood spot test exhibits a clear dominance in the market owing to its simplicity, cost-effectiveness, and ability to collect and store samples efficiently.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position in the newborn screening market on account of its advanced healthcare infrastructure, extensive screening programs, and strong government support for early detection initiatives.

Research Methodology:

The report employs a comprehensive research methodology, combining primary and secondary data sources to validate findings. It includes market assessments, surveys, expert opinions, and data triangulation techniques to ensure accuracy and reliability.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145